Terms: = Lung cancer AND CEACAM5, CEA AND Staging
120 results:
1. HBB as a Novel Biomarker for the Diagnosis and Monitoring of lung cancer Regulates Cell Proliferation via ERK1/2 Pathway.
Xu X; Cai H; Peng J; Liu H; Chu F
Technol Cancer Res Treat; 2024; 23():15330338241249032. PubMed ID: 38679728
[No Abstract] [Full Text] [Related]
2. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract] [Full Text] [Related]
3. Correlation Analysis of KCNQ1 Gene Polymorphism with Blood Indexes and Prognosis of Non-Small Cell lung cancer.
Xie G; Yang Y; Zeng W; Liu Y; Gui B
Clin Lab; 2024 Feb; 70(2):. PubMed ID: 38345992
[TBL] [Abstract] [Full Text] [Related]
4. Mesenteric Castleman Disease Misdiagnosed as Lymph Node Metastasis of Rectal cancer on 18 F-FDG PET/CT.
Liu M; Zhou J; Zhu W; Huo L; Cheng W
Clin Nucl Med; 2023 Nov; 48(11):985-986. PubMed ID: 37703486
[TBL] [Abstract] [Full Text] [Related]
5. Combination of ceacam5, EpCAM and CK19 gene expressions in mediastinal lymph node micrometastasis is a prognostic factor for non-small cell lung cancer.
Süer H; Erus S; Cesur EE; Yavuz Ö; Ağcaoğlu O; Bulutay P; Önder TT; Tanju S; Dilege Ş
J Cardiothorac Surg; 2023 Jun; 18(1):189. PubMed ID: 37312199
[TBL] [Abstract] [Full Text] [Related]
6. Lymph node metastasis risk factors in clinical stage IA3 lung adenocarcinoma.
Zheng Y; Ju S; Huang R; Zhao J
J Cancer Res Ther; 2023 Feb; 19(1):34-38. PubMed ID: 37006040
[TBL] [Abstract] [Full Text] [Related]
7. Ratiometric electrochemical OR gate assay for NSCLC-derived exosomes.
Meng F; Yu W; Niu M; Tian X; Miao Y; Li X; Zhou Y; Ma L; Zhang X; Qian K; Yu Y; Wang J; Huang L
J Nanobiotechnology; 2023 Mar; 21(1):104. PubMed ID: 36964516
[TBL] [Abstract] [Full Text] [Related]
8. Detection of Changes in cea and ProGRP Levels in BALF of Patients with Peripheral lung cancer and the Relationship with CT Signs.
Huang J; Ren K
Contrast Media Mol Imaging; 2023; 2023():1421709. PubMed ID: 36851977
[TBL] [Abstract] [Full Text] [Related]
9. Diagnostic value of lncRNA HOTAIR as a biomarker for detecting and staging of non-small cell lung cancer.
Yao X; Wang T; Sun MY; Yuming Y; Guixin D; Liu J
Biomarkers; 2022 Sep; 27(6):526-533. PubMed ID: 35959801
[No Abstract] [Full Text] [Related]
10. [On detection of chromogranin A, synaptophysin, neuronspecific enolase and progastrin-releasing peptide in small cell lung cancer].
Lu QQ; Li J; Li YH; Liu H; Xie XB
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jul; 56(7):1017-1022. PubMed ID: 35899358
[TBL] [Abstract] [Full Text] [Related]
11. Diagnostic value of HSP90α and related markers in lung cancer.
Yuan Z; Wang L; Hong S; Shi C; Yuan B
J Clin Lab Anal; 2022 Jun; 36(6):e24462. PubMed ID: 35522136
[TBL] [Abstract] [Full Text] [Related]
12. Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal cancer (PerSeUS-RC01).
Matsuhashi N; Takahashi T; Tanaka C; Yawata K; Yamada M; Iwata Y; Kiyama S; Mizutani C; Tajima JY; Ishihara T; Yoshida K
Anticancer Res; 2021 Dec; 41(12):6247-6257. PubMed ID: 34848480
[TBL] [Abstract] [Full Text] [Related]
13. Cost-effectiveness analysis with unordered decisions.
Díez FJ; Luque M; Arias M; Pérez-Martín J
Artif Intell Med; 2021 Jul; 117():102064. PubMed ID: 34127243
[TBL] [Abstract] [Full Text] [Related]
14. [Prognostic factor analysis of patients with unresectablelung squamous cell carcinoma].
Gao X; Li Z; Shao XY; Liu XM; Liu C; Liu YP; Qu XJ; Zhang LY
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):569-573. PubMed ID: 34034477
[No Abstract] [Full Text] [Related]
15. Genetic Mutation Analysis in Small Cell lung cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features.
Jin W; Lei Z; Xu S; Fachen Z; Yixiang Z; Shilei Z; Tao G; Zhe S; Fengzhou L; Su WH; Chundong G
Biomed Res Int; 2021; 2021():3609028. PubMed ID: 33880365
[TBL] [Abstract] [Full Text] [Related]
16. Clinical T1aN0M0 lung cancer: differences in clinicopathological patterns and oncological outcomes based on the findings on high-resolution computed tomography.
Sun K; You A; Wang B; Song N; Wan Z; Wu F; Zhao W; Zhou F; Li W
Eur Radiol; 2021 Oct; 31(10):7353-7362. PubMed ID: 33860370
[TBL] [Abstract] [Full Text] [Related]
17. Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer.
Cui Y; Wang W; Yao S; Qiu Z; Cong L
J Cancer Res Ther; 2020; 16(7):1641-1647. PubMed ID: 33565511
[TBL] [Abstract] [Full Text] [Related]
18. Molecular Nodal Restaging Based on ceacam5, FGFR2b and PTPN11 Expression Adds No Relevant Clinical Information in Resected Non-Small Cell lung cancer.
Macia I; Aiza G; Ramos R; Escobar I; Rivas F; Ureña A; Aso S; Rosado G; Rodriguez-Taboada P; Deniz C; Nadal E; Capella G
J Invest Surg; 2022 Feb; 35(2):315-324. PubMed ID: 33342327
[TBL] [Abstract] [Full Text] [Related]
19. Elevated preoperative cea is associated with subclinical nodal involvement and worse survival in stage I non-small cell lung cancer: a systematic review and meta-analysis.
Nasralla A; Lee J; Dang J; Turner S
J Cardiothorac Surg; 2020 Oct; 15(1):318. PubMed ID: 33059696
[TBL] [Abstract] [Full Text] [Related]
20. Detection of CTCs and CSCs in the staging and metastasis of non-small cell lung cancer based on microfluidic chip and the diagnostic significance.
Wang SQ; Shuai ZF; Zhang XJ; Wu T; Dong HY; Liu T; Wen QT; Yu XW
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9487-9496. PubMed ID: 33015791
[TBL] [Abstract] [Full Text] [Related]
[Next]
